glp-1 receptor antagonist Glucagon-like peptide-1 Exploring the Side Effects of

We've got answers

Data from the Centers for Disease Control and Prevention (CDC) in 2023 indicated that more than 37 million adults in the United States were living with diabetes, while obesity rates remained considerably high across the region

Here are the health stories we're watching in 2025 Wegovy is a weight-loss drug

revenue for Novo Nordisk and Eli Lillys GLP-1 products using the active ingredients semaglutide and tirzepatide, beginning with the first full year of sales post-launch and through 2024

Because exendin-4 and GLP-1 are similar, it became possible to treat the disease using venom

Because retatrutide is not yet licensed in the UK, individuals are unlikely to encounter it outside of a formal clinical trial setting